𝛼SK or Searchbullish
LEGN: 2Q26 Call Takeaways; 2026 Profitability on Track; Next up on LB2501 (In Vivo CAR-T) Updates
108 Views12 Aug 2026 13:25
2Q26 profitability on track, with Carvykti sales up 50% YoY and operating margin of 15%; LEGN 2H26 key catalysts: continued QoQ Carvykti growth + additional in vivo CAR-T data
What is covered in the Full Insight:
- Introduction to 2Q26 Performance
- Carvykti Sales Growth Analysis
- Financial Guidance and Cash Position
- LB2501 Development Update
- Key Strategic Objectives for 2026
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- China Healthcare Weekly Wrap (17-21 Aug)24 Aug 2026
- Hengrui (600276.CH): 2Q26 Miss on Generic Drugs Decline and Moderating Growth of Oncology Segment21 Aug 2026
- Genscript (1548.HK): 1H26 Results Driven by AI Orders; Guidance Upgrades on Life-Science and Probio17 Aug 2026
- LEGN: 2Q26 Call Takeaways; 2026 Profitability on Track; Next up on LB2501 (In Vivo CAR-T) Updates12 Aug 2026
- China Healthcare Weekly Wrap (3-7 Aug)08 Aug 2026
- BeOne (ONC.US): 2Q Results Call Takeaway; 2026 Guidance Raised on Strength of Brukinsa; Next up ESMO05 Aug 2026
x